Advanced search
Publication Cover
Emerging Microbes & Infections Volume 10, 2021 - Issue 1
Submit an article Journal homepage
22,032
Views
106
CrossRef citations to date
0
Altmetric
Coronaviruses

Antibody titres decline 3-month post-vaccination with BNT162b2

Julien Favressea Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium;b Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, BelgiumCorrespondence[email protected]
,
Jean-Louis Bayartc Department of Laboratory Medicine, Clinique St-Pierre, Ottignies, Belgium
,
François Mullierd Department of Laboratory Medicine, Université catholique de Louvain, CHU UCL Namur, Namur, BelgiumORCID Iconhttps://orcid.org/0000-0001-6947-6099
ORCID Icon,
Marc Elsena Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium
,
Christine Euchera Department of Laboratory Medicine, Clinique St-Luc Bouge, Namur, Belgium
,
Sandrine Van Eeckhoudte Department of Internal Medicine, Clinique St-Luc Bouge, Namur, Belgium
,
Tatiana Royc Department of Laboratory Medicine, Clinique St-Pierre, Ottignies, Belgium
,
Gregoire Wieersf Department of Internal Medicine, Clinique St-Pierre, Ottignies, Belgium
,
Christine Laurentg Department of Internal Medicine, Université catholique de Louvain, CHU UCL Namur, Namur, Belgium
,
Jean-Michel Dognéb Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium
,
Mélanie Clossetd Department of Laboratory Medicine, Université catholique de Louvain, CHU UCL Namur, Namur, Belgium
&
Jonathan Douxfilsb Department of Pharmacy, Namur Research Institute for LIfe Sciences, University of Namur, Namur, Belgium;h Qualiblood sa, Namur, BelgiumORCID Iconhttps://orcid.org/0000-0002-7644-5298
ORCID Icon show all
Pages 1495-1498 | Received 07 Jun 2021, Accepted 05 Jul 2021, Published online: 22 Jul 2021

References

  • Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383:2603–2615.
  • Ebinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021;27:981–984.
  • Favresse J, Bayart JL, Mullier F, et al. Early antibody response in healthcare professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2). Clin Microbiol Infect. 2021. doi:https://doi.org/10.1016/j.cmi.2021.05.004. Online ahead of print.
  • Padoan A, Dall'Olmo L, Rocca FD, et al. Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers. Clin Chim Acta. 2021;519:60–63.
  • Tré-Hardy M, Cupaiolo R, Papleux E, et al. Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers. J Infect. 2021. doi:https://doi.org/10.1016/j.jinf.2021.03.025. Online ahead of print.
  • Salvagno GL, Henry BM, di Piazza G, et al. Anti-SARS-CoV-2 receptor-binding domain total antibodies response in seropositive and seronegative healthcare workers undergoing COVID-19 mRNA BNT162b2 vaccination. Diagnostics. 2021;11:832.
  • Favresse J, Eucher C, Elsen M, et al. Clinical performance of the Elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies. Clin Chem. 2020;66:1104–1106.
  • Favresse J, Eucher C, Elsen M, et al. Persistence of anti-SARS-CoV-2 antibodies depends on the analytical Kit: A report for Up to 10 months after infection. Microorganisms. 2021;9:556.
  • Schaffner A, Risch L, Aeschbacher S, et al. Characterization of a Pan-immunoglobulin assay quantifying antibodies directed against the receptor binding domain of the SARS-CoV-2 S1-subunit of the spike protein: a population-Based study. J Clin Med. 2020;9:3889.
  • Rubin R. COVID-19 vaccines vs variants—determining How much immunity is enough. JAMA. 2021;325:1241.
  • Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021. doi:https://doi.org/10.1038/s41591-021-01377-8. Online ahead of print.
  • L'Huillier AG, Meyer B, Andrey DO, et al. Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study. Clin Microbiol Infect. 2021;27:784.e1–784.e8.
  • Doria-Rose N, Suthar MS, Makowski M, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for covid-19. N Engl J Med. 2021;384:2259–2261.
  • Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:4063.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.